Voyager Therapeutics (VYGR) Amortization of Deferred Charges (2024 - 2026)

Voyager Therapeutics (VYGR) has 3 years of Amortization of Deferred Charges data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Amortization of Deferred Charges rose 3.93% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.9 million (up 3.32% YoY), and the FY2025 full-year result was $4.9 million, up 5.96% from the prior year.
• Amortization of Deferred Charges climbed to $1.3 million in Q1 2026, from $1.3 million in the prior quarter.
• In the past five years, Amortization of Deferred Charges ranged from a high of $1.4 million in Q2 2024 to a low of $991000.0 in Q3 2024.
• A 3-year average of $1.2 million and a median of $1.2 million in 2025 frame the typical range for Amortization of Deferred Charges.
• Peak annual rise in Amortization of Deferred Charges reached 24.42% in 2025, while the deepest fall reached 16.0% in 2025.
• Tracing VYGR's Amortization of Deferred Charges over 3 years: stood at $1.2 million in 2024, then climbed by 7.5% to $1.3 million in 2025, then grew by 0.55% to $1.3 million in 2026.
• Business Quant data shows VYGR's Amortization of Deferred Charges at $1.3 million in Q1 2026, $1.3 million in Q4 2025, and $1.2 million in Q3 2025.